Therapy Areas: Oncology
Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013
24 July 2026 - Commercial-stage pharmaceutical company Bio-Thera Solutions Ltd (SH:688177) announced on Thursday that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug ...
EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer
23 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Thursday it has secured European Union approval for Etcamah (camizestrant) combined with a CDK4/6 ...
BeOne Medicines expands US manufacturing with USD300m investment
23 July 2026 - Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that it will invest USD300m to expand its flagship manufacturing and research and devel...
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
23 July 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhib...
Greenwich LifeSciences secures UK approval to expand Phase III breast cancer trial
22 July 2026 - US biopharmaceutical company Greenwich LifeSciences, Inc. (NASDAQ: GLSI) said on Wednesday it has received regulatory clearance to extend its Phase III FLAMINGO-01 trial into the United...
Elephas Biosciences partners with Invitrocue to promote elive platform in Singapore and Malaysia
22 July 2026 - Elephas Biosciences Corporation, developer of an innovative live tissue platform for immunotherapy response prediction, announced on Tuesday that it has entered into an international pa...